A5053329398- Bipolar Disorder and Treatment
- Schizophrenia research and treatment
- Neuroscience and Neuropharmacology Research
- Electroconvulsive Therapy Studies
- Pharmacological Effects and Toxicity Studies
- Adolescent and Pediatric Healthcare
- Epilepsy research and treatment
- Treatment of Major Depression
- Child and Adolescent Psychosocial and Emotional Development
- Tryptophan and brain disorders
- Functional Brain Connectivity Studies
- Stress Responses and Cortisol
- Neurotransmitter Receptor Influence on Behavior
- Electrolyte and hormonal disorders
- Mental Health Research Topics
- Transcranial Magnetic Stimulation Studies
- Ion channel regulation and function
- Neuroendocrine regulation and behavior
- Neurological disorders and treatments
- Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Memory and Neural Mechanisms
- Receptor Mechanisms and Signaling
- Attention Deficit Hyperactivity Disorder
- Psychosomatic Disorders and Their Treatments
- Neuropeptides and Animal Physiology
University of Bonn
2025
The University of Texas Southwestern Medical Center
2003-2023
University of California, Los Angeles
2003-2023
VA Greater Los Angeles Healthcare System
2023
George Washington University
2013-2022
Collaborative Group (United States)
2013-2022
Yale University
1996-2016
University Medical Center Groningen
2014-2016
VA Palo Alto Health Care System
2016
Mayo Clinic in Arizona
2016
Bipolar spectrum disorders, which include bipolar I, II, and disorder not otherwise specified, frequently go unrecognized, undiagnosed, untreated. This report describes the validation of a new brief self-report screening instrument for disorders called Mood Disorder Questionnaire.A total 198 patients attending five outpatient clinics that primarily treat with mood completed Questionnaire. A research professional, blind to Questionnaire results, conducted telephone diagnostic interview by...
The Canadian Network for Mood and Anxiety Treatments (CANMAT) previously published treatment guidelines bipolar disorder in 2005, along with international commentaries subsequent updates 2007, 2009, 2013. last two were collaboration the International Society Bipolar Disorders (ISBD). These 2018 CANMAT ISBD Treatment Guidelines represent significant advances field since full edition was including to diagnosis management as well new research into pharmacological psychological treatments. have...
Converging evidence points to hypofunction of the left prefrontal cortex in depression. Repetitive transcranial magnetic stimulation (rTMS) activates neurons near surface brain. We questioned whether daily rTMS might improve mood depressed subjects and report a pilot study such treatment six highly medication-resistant inpatients. Depression scores significantly improved for group as whole (Hamilton Scores decreased from 23.8 ± 4.2 (s.d.) at baseline 17.5 8.4 after treatment; t = 3.03, 5DF,...
Primary depression can be associated with substantial hypercortisolism, thus prompting some researchers to suggest that shares pathophysiologic features Cushing's disease. Clinically, difficult or impossible distinguish from mild early disease is depressive features. The purpose of this study was evaluate whether the pituitary-adrenal responses ovine corticotropin-releasing hormone could help clarify mechanism hypercortisolism in and assist differential diagnosis these disorders. As compared...
The risk-benefit profile of antidepressant medications in bipolar disorder is controversial. When conclusive evidence lacking, expert consensus can guide treatment decisions. International Society for Bipolar Disorders (ISBD) convened a task force to seek recommendations on the use antidepressants disorders.An iteratively developed through serial consensus-based revisions using Delphi method. Initial survey items were based systematic review literature. Subsequent surveys included new or...
The authors evaluated carbamazepine (Tegretol), a drug of choice for treatment temporal lobe epilepsy, in double-blind placebo-controlled trial patients with manic-depressive illness. Seven 9 manic had partial to marked response; several also showed relapses when placebo was substituted and improvement reinstituted. Five 13 depressed significant depression ratings; 3 additional experienced relapse substituted. Carbamazepine might have prophylactic as well acute efficacy both phases illness,...
There is a pressing need for additional treatment options refractory mood disorders. This controlled comparative study evaluated the efficacy of lamotrigine (LTG) and gabapentin (GBP) monotherapy versus placebo (PLC). Thirty-one patients with bipolar unipolar disorders participated in double-blind, randomized, crossover series three 6-week evaluations including LTG, GBP, PLC. was standardized blinded titration to assess clinical or determine maximum tolerated daily dose (LTG 500 mg GBP 4,800...
Article Abstract Background: A number of recent longitudinal outcome studies have found substantial long-term morbidity in patients with bipolar disorder. The detailed course and pattern illness emerging despite comprehensive treatment mood stabilizers adjunctive agents previously not been well delineated. Method: 258 consecutive outpatients admitted from 1996 to 1999 the Stanley Foundation Bipolar Network who had a full year prospective daily clinician ratings on National Institute Mental...
OBJECTIVE: The authors examined the comparative risks of switches in mood polarity into hypomania or mania during acute and continuation trials adjunctive antidepressant treatment bipolar depression. METHOD: One hundred fifty-nine patients with I disorder II participated a total 228 (10-week) randomized bupropion, sertraline, venlafaxine as an adjunct to stabilizer. Patients 87 these entered for up 1 year. Antidepressant response occurrence subthreshold brief (emergence [at least but <7...
Using data gathered in a naturalistic study of 95 research patients at the NIMH, retrospective method documenting life course recurrent affective illness is presented, along with partial prospective validation this method. In these patients, severity, frequency, and duration manic depressive episodes, as well their pattern distribution, are characterized. These variables examined different subgrouped according to gender age onset, polarity, rapidity cycling illness. The findings compared on...
Objectives: To assess the proportion of time spent in mania, depression and euthymia a large cohort bipolar subjects studied longitudinally, to investigate depression/mania ratios patients with I versus II disorder. Methods: Clinician‐adjusted self‐ratings mood were completed daily for one year naturalistically treated outpatients (n = 405) or 102) Ratings analyzed mean euthymic, depressed, manic, hypomanic, cycling, percentages ill compared between two groups. Results: Percentages were:...
Article Abstract Objective: We examined the influence of age at onset illness and delay in time to first treatment on morbidity adulthood. Method: 529 adult outpatients with a mean 42 years, who entered our research network from 1996 through 2001 were diagnosed bipolar disorder according DSM-IV criteria, rated prospectively daily basis National Institute Mental Health-Life Chart Method during naturalistic for up 4 years. Results: Fifty percent patients had childhood (< 13 years age) or...
Background Few studies have examined the relative risks of switching into hypomania or mania associated with second-generation antidepressant drugs in bipolar depression. Aims To examine acute effects bupropion, sertraline and venlafaxine as adjuncts to mood stabilisers. Method In a 10-week trial, participants receiving out-patient treatment for disorder (stratified rapid cycling) were randomly treated flexible dose one antidepressants, their respective matching placebos, Results A total 174...